Table 4.
Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in the 94 patients with NVR of past IFN treatment
| Patients with Vs ≧ 1.55 m/s | Patients with Vs < 1.55 m/s | Comparison between patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s | Multiple regression analysis for factors associated with ≧ 1.55 m/s | ||
|---|---|---|---|---|---|
| (n = 45) | (n = 49) | Odds ratio (95% confidence interval) | p | ||
| Age (yrs) | 64.3±9.4 | 57.7±10.9 | P = 0.0026 | 1.03 (1.03 - 1.13) | p = 0.0023 |
| Gender (male/female) | 18/27 | 21/28 | NS | NS | |
| BMI (kg/m2) | 23.7±3.8 | 22.2±2.8 | P = 0.0274 | 1.20 (1.04 - 1.39) | p = 0.0156 |
| PNPLA3 (GG/CC・CG) | 10/35 | 9/40 | NS | ||
| AST (IU/L) | 59.6±22.0 | 51.7±63.9 | NS | ||
| ALT (IU/L) | 58.6±31.2 | 62.8±98.8 | NS | ||
| γ-GTP (IU/L) | 57.2±37.1 | 62.1±122.7 | NS | ||
| Albumin (g/dL) | 3.9±0.7 | 4.4±0.3 | p < 0.0001 | ||
| Total bilirubin (mg/dL) | 0.9±0.3 | 1.0±1.4 | NS | ||
| Platelet count (x104/μL) | 11.1±4.4 | 16.7±5.1 | p < 0.0001 | ||
| Prothrombin time (%) | 88.5±14.1 | 104.0±16.5 | p < 0.0001 | ||
| Hyaluronic acid (ng/mL) | 305.2±229.7 | 89.3±170.5 | p < 0.0001 | ||
| α-fetoprotein (ng/mL) | 20.1±18.0 | 4.9±3.6 | p < 0.0001 | ||
| PIVKA-II(mAU/mL) | 23.5±13.9 | 19.9±9.3 | NS | ||
| HCV genotype (1/2/3) | 40/4/1 | 39/10/0 | NS | ||
| HCV RNA (log IU/mL) | 6.3±0.9 | 6.0±1.3 | NS | ||
| Velocity of shear wave (m/s) | 2.20±0.50 | 1.23±0.16 | p < 0.0001 | ||
| Hepatocellular carcnoma (present/absent) | 14/31 | 3/46 | P = 0.0017 | ||
NVR, non-virological response; IFN, interferon; Vs, velocity of shear wave; BMI, body mass index; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II ; NS, not significant.